# US 2013/0288387 A1 · Anti-hla monoclonal chimeric immunoglobulin, process and kit employing such a monoclonal chimeric immunoglobulin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0288387 A1
- Document ID: US20130288387A1
- Status: Published application
- Kind: A1
- Application number: 13/869,477
- Filed: 2013-04-24
- Published: 2013-10-31
- Earliest claimed: 2012-04-27
- Assignees: Universite Paul Sabatier Toulouse III; Cayla; Centre Hospitalier Universitaire De Toulouse
- Applicants: Universite Paul Sabatier Toulouse III; Cayla; Centre Hospitalier Universitaire De Toulouse
- Inventors: Antoine BLANCHER; Nicolas CONGY; Jean-Gerard TIRABY; Daniel DROCOURT
- Web page: https://patentgrep.com/patent/US20130288387A1

## CPC

- C07K 16/18: against material from animals or humans
- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- G01N 33/56977: {HLA or MHC typing}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A monoclonal chimeric immunoglobulin wherein the heavy chains and the light chains are human by nature in their constant parts, in particular, the heavy chain constant parts are chosen from the group formed of the heavy chain constant parts of an IgA, of an IgG or of an IgM and the light chain constant parts are chosen from the group formed of the kappa chains and the lambda chains, and the light chain and the heavy chain variable parts are chosen from the group formed of monoclonal antibodies specific to monomorphic epitopes of HLA class I antigens and monoclonal antibodies specific to monomorphic epitopes of HLA class II antigens. A process for standardization of the screening and for quantification of anti-HLA antibodies in a liquid medium is also described.

## Claims

### Claim 1

Monoclonal chimeric immunoglobulin formed of:
two polypeptide chains, called heavy chains (H), of molecular weight from 40 kDa to 60 kDa, and
two polypeptide chains, called light chains (L), of molecular weight from 20 kDa to 30 kDa,
wherein
each heavy chain (H) comprises:
a heavy chain variable region (VH) of a monoclonal antibody chosen from the group formed of monoclonal antibodies specific to monomorphic epitopes of HLA class I antigens and monoclonal antibodies specific to monomorphic epitopes of HLA class II antigens, and
a heavy chain constant region (CH) of a human immunoglobulin chosen from the group formed of IgAs, IgGs and IgMs,
and in that
each light chain (L) comprises:
a light chain variable region (VL) of a monoclonal antibody chosen from the group formed of monoclonal antibodies specific to monomorphic epitopes of HLA class I antigens and monoclonal antibodies specific to monomorphic epitopes of HLA class II antigens, and
a light chain constant region (CL) of a human immunoglobulin chosen from the group formed of the kappa chains and the lambda chains.

### Claim 2 (depends on 1)

Monoclonal chimeric immunoglobulin as claimed in claim 1, wherein each monoclonal antibody specific to monomorphic epitopes of HLA class I antigens and each monoclonal antibody specific to monomorphic epitopes of HLA class II antigens is chosen from the group formed of the monoclonal antibodies of a vertebrate.

### Claim 3 (depends on 1)

Monoclonal chimeric immunoglobulin as claimed in claim 1, wherein the monoclonal antibody specific to monomorphic epitopes of HLA class I antigens is the W6/32 antibody.

### Claim 4 (depends on 1)

Monoclonal chimeric immunoglobulin as claimed in claim 1, wherein the monoclonal antibody specific to monomorphic epitopes of the HLA class II antigen is the F.3.3 antibody.

### Claim 5

(canceled)

### Claim 6

Process for the determination of the quantity of anti-HLA antibodies in a liquid medium containing antibodies, wherein:
a plurality of solutions (Sn) of a monoclonal chimeric immunoglobulin is prepared, each solution (Sn) having a defined concentration value (Cn) of said monoclonal chimeric immunoglobulin, and then
each solution (Sn) is placed in contact with the same defined quantity of at least one immobilised HLA antigen, and
a calibration curve is produced, in which each defined concentration value (Cn) is associated with a measured value (Vn) of a parameter, said measured value (Vn) representing a quantity (Qn) of the monoclonal chimeric immunoglobulin linked to the defined quantity of each immobilised HLA antigen,
in which process the monoclonal chimeric immunoglobulin is formed of:
two polypeptide chains, called heavy chains (H), of molecular weight from 40 kDa to 60 kDa, and
two polypeptide chains, called light chains (L), of molecular weight from 20 kDa to 30 kDa,
wherein:
each heavy chain (H) comprises:
a heavy chain variable region (VH) of a monoclonal antibody chosen from the group formed of monoclonal antibodies specific to monomorphic epitopes of HLA class I antigens and monoclonal antibodies specific to monomorphic epitopes of HLA class II antigens, and
a heavy chain constant region (CH) of a human immunoglobulin chosen from the group formed of IgAs, IgGs and IgMs,
and in that
each light chain (L) comprises:
a light chain variable region (VL) of a monoclonal antibody chosen from the group formed of monoclonal antibodies specific to monomorphic epitopes of HLA class I antigens and monoclonal antibodies specific to monomorphic epitopes of HLA class II antigens, and
a light chain constant region (CL) of a human immunoglobulin chosen from the group formed of the kappa chains and the lambda chains.

### Claim 7 (depends on 6)

Process as claimed in claim 6, wherein, in order to produce the calibration curve:
there is formed, from pairs (Cn, Vn) of defined concentration (Cn) and measured value (Vn), the calibration curve showing the variation of the measured value (Vn) as a function of the defined concentration (Cn) of monoclonal chimeric immunoglobulin of each solution (Sn) of monoclonal chimeric immunoglobulin, and
there is calculated a value, called a threshold value, of the fluorescence parameter beyond which the concentration of monoclonal chimeric immunoglobulin is significantly greater than 0.

### Claim 8 (depends on 6)

Process as claimed in claim 6, wherein each monoclonal antibody specific to monomorphic epitopes of HLA class I antigens and each monoclonal antibody specific to monomorphic epitopes of HLA class II antigens is chosen from the group formed of the monoclonal antibodies of a vertebrate.

### Claim 9 (depends on 6)

Process as claimed in claim 6, wherein the parameter is chosen from the group formed of fluorescence parameters, luminescence parameters and colorimetry parameters.

### Claim 10 (depends on 9)

Process as claimed in claim 9, wherein the fluorescence parameter is a fluorescence intensity.

### Claim 11 (depends on 6)

Process as claimed in claim 6, wherein:
a) each immobilised HLA antigen being an HLA antigen immobilised on a solid substrate in the divided state formed of particles,
b) the immobilised HLA antigens and each solution of monoclonal chimeric immunoglobulin directed against the HLA antigens of the solid substrate are brought into contact under conditions suitable for forming a stable bond between the HLA antigens of the solid substrate and the monoclonal chimeric immunoglobulin of each solution of monoclonal chimeric immunoglobulin, and then
c) the monoclonal chimeric immunoglobulins that are not bound to the HLA antigens of the solid substrate are removed by washing, and then
d) the monoclonal chimeric immunoglobulins that are bound to the HLA antigens of the solid substrate are brought into contact with a solution of a secondary antibody which is chosen from the group formed of fluorescent secondary antibodies, luminescent secondary antibodies and photoabsorbent secondary antibodies and which is directed against the monoclonal chimeric immunoglobulin, under conditions suitable for forming a stable bond between the monoclonal chimeric immunoglobulin and the secondary antibody, and then
e) the secondary antibody that is not bound to the monoclonal chimeric immunoglobulin is removed by washing, and then
f) at least one parameter of the secondary antibody that is bound to each particle of the solid substrate is measured, and there is assigned to that measurement a measured value (Vn) of said parameter chosen from the group formed of a fluorescence parameter, a luminescence parameter and a colorimetry parameter, and then
g) the calibration curve is formed, and then
h) there is derived from the calibration curve a fluorescence intensity threshold value indicating the presence of the anti-HLA antibody in a solution to be analysed.

### Claim 12 (depends on 6)

Process as claimed in claim 6, wherein each immobilised HLA antigen is an HLA antigen presented at the surface of at least one cell.

### Claim 13 (depends on 6)

Process as claimed in claim 6, wherein the monoclonal antibody specific to monomorphic epitopes of HLA class I antigens is the W6/32 antibody.

### Claim 14 (depends on 6)

Process as claimed in claim 6, wherein the monoclonal antibody specific to monomorphic epitopes of HLA class II antigens is the F.3.3 antibody.

### Claim 15

Kit for the quantification of anti-HLA antibodies in a liquid medium, said kit comprising at least one monoclonal chimeric immunoglobulin comprising:
two polypeptide chains, called heavy chains (H), of molecular weight from 40 kDa to 60 kDa, and
two polypeptide chains, called light chains (L), of molecular weight from 20 kDa to 30 kDa,
wherein
each heavy chain (H) comprises:
a heavy chain variable region (VH) of a monoclonal antibody chosen from the group formed of monoclonal antibodies specific to monomorphic epitopes of HLA class I antigens and monoclonal antibodies specific to monomorphic epitopes of HLA class II antigens, and
a heavy chain constant region (CH) of a human immunoglobulin chosen from the group formed of IgAs, IgGs and IgMs,
and in that
each light chain (L) comprises:
a light chain variable region (VL) of a monoclonal antibody chosen from the group formed of monoclonal antibodies of a non-human vertebrate organism specific to monomorphic epitopes of HLA class I antigens and monoclonal antibodies specific to monomorphic epitopes of HLA class II antigens, and
a light chain constant region (CL) of a human immunoglobulin chosen from the group formed of the kappa chains and the lambda chains.

### Claim 16 (depends on 2)

Monoclonal chimeric immunoglobulin as claimed in claim 2, wherein the monoclonal antibody specific to monomorphic epitopes of HLA class I antigens is the W6/32 antibody.

### Claim 17 (depends on 2)

Monoclonal chimeric immunoglobulin as claimed in claim 2, wherein the monoclonal antibody specific to monomorphic epitopes of the HLA class II antigen is the F.3.3 antibody.

### Claim 18 (depends on 7)

Process as claimed in claim 7, wherein each monoclonal antibody specific to monomorphic epitopes of HLA class I antigens and each monoclonal antibody specific to monomorphic epitopes of HLA class II antigens is chosen from the group formed of the monoclonal antibodies of a vertebrate.
